Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy
Biomarkers that are able to predict the response to omalizumab (OMA) in chronic spontaneous urticaria (CSU) are highly valued. The aim of our study was to evaluate the UAS7 (urticaria activity score assessed for 7 days), DLQI (dermatology life quality index), SII (systemic immune-inflammation index)...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/7/2639 |
| _version_ | 1797607662556282880 |
|---|---|
| author | Bartłomiej Tarkowski Julia Ławniczak Katarzyna Tomaszewska Marcin Kurowski Anna Zalewska-Janowska |
| author_facet | Bartłomiej Tarkowski Julia Ławniczak Katarzyna Tomaszewska Marcin Kurowski Anna Zalewska-Janowska |
| author_sort | Bartłomiej Tarkowski |
| collection | DOAJ |
| description | Biomarkers that are able to predict the response to omalizumab (OMA) in chronic spontaneous urticaria (CSU) are highly valued. The aim of our study was to evaluate the UAS7 (urticaria activity score assessed for 7 days), DLQI (dermatology life quality index), SII (systemic immune-inflammation index), SIRI (systemic inflammation response index), PLR (platelet/lymphocyte ratio) and NLR (neutrophil/lymphocyte ratio) in a group of 46 CSU a patients treated for 24 weeks with OMA (300 mg every 4 weeks). There were no statistically significant differences observed at the start nor at the end of the treatment between the two groups (responders vs. non-responders) and SII, SIRI, PLR and NLR. However, a statistically significant correlation was observed between severity of urticaria expressed in UAS7 scores and the quality of life (evaluated by DLQI). Furthermore, at week 24, both groups demonstrated significant improvement in quality of life. Our single center study did not confirm the usefulness of SII, SIRI, NLR or PLR as predictors of the response to OMA in CSU. However, it is of importance that even patients who did not respond to the treatment presented a significant improvement in quality of life. Additionally, we also observed that the efficacy of treatment was unchanged amongst patients who underwent a second series of treatment in cases of relapse. |
| first_indexed | 2024-03-11T05:33:00Z |
| format | Article |
| id | doaj.art-98f03d37ecf440b084c6f3660f69284f |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T05:33:00Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-98f03d37ecf440b084c6f3660f69284f2023-11-17T16:59:52ZengMDPI AGJournal of Clinical Medicine2077-03832023-04-01127263910.3390/jcm12072639Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment EfficacyBartłomiej Tarkowski0Julia Ławniczak1Katarzyna Tomaszewska2Marcin Kurowski3Anna Zalewska-Janowska4Psychodermatology Department, Medical University of Lodz, 92-213 Lodz, PolandFaculty of Medicine, Medical University of Lodz, 92-213 Lodz, PolandPsychodermatology Department, Medical University of Lodz, 92-213 Lodz, PolandDepartment of Immunology and Allergy, Medical University of Lodz, 92-213 Lodz, PolandPsychodermatology Department, Medical University of Lodz, 92-213 Lodz, PolandBiomarkers that are able to predict the response to omalizumab (OMA) in chronic spontaneous urticaria (CSU) are highly valued. The aim of our study was to evaluate the UAS7 (urticaria activity score assessed for 7 days), DLQI (dermatology life quality index), SII (systemic immune-inflammation index), SIRI (systemic inflammation response index), PLR (platelet/lymphocyte ratio) and NLR (neutrophil/lymphocyte ratio) in a group of 46 CSU a patients treated for 24 weeks with OMA (300 mg every 4 weeks). There were no statistically significant differences observed at the start nor at the end of the treatment between the two groups (responders vs. non-responders) and SII, SIRI, PLR and NLR. However, a statistically significant correlation was observed between severity of urticaria expressed in UAS7 scores and the quality of life (evaluated by DLQI). Furthermore, at week 24, both groups demonstrated significant improvement in quality of life. Our single center study did not confirm the usefulness of SII, SIRI, NLR or PLR as predictors of the response to OMA in CSU. However, it is of importance that even patients who did not respond to the treatment presented a significant improvement in quality of life. Additionally, we also observed that the efficacy of treatment was unchanged amongst patients who underwent a second series of treatment in cases of relapse.https://www.mdpi.com/2077-0383/12/7/2639chronic spontaneous urticariaomalizumabpredictors |
| spellingShingle | Bartłomiej Tarkowski Julia Ławniczak Katarzyna Tomaszewska Marcin Kurowski Anna Zalewska-Janowska Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy Journal of Clinical Medicine chronic spontaneous urticaria omalizumab predictors |
| title | Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy |
| title_full | Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy |
| title_fullStr | Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy |
| title_full_unstemmed | Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy |
| title_short | Chronic Urticaria Treatment with Omalizumab—Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy |
| title_sort | chronic urticaria treatment with omalizumab verification of nlr plr siri and sii as biomarkers and predictors of treatment efficacy |
| topic | chronic spontaneous urticaria omalizumab predictors |
| url | https://www.mdpi.com/2077-0383/12/7/2639 |
| work_keys_str_mv | AT bartłomiejtarkowski chronicurticariatreatmentwithomalizumabverificationofnlrplrsiriandsiiasbiomarkersandpredictorsoftreatmentefficacy AT juliaławniczak chronicurticariatreatmentwithomalizumabverificationofnlrplrsiriandsiiasbiomarkersandpredictorsoftreatmentefficacy AT katarzynatomaszewska chronicurticariatreatmentwithomalizumabverificationofnlrplrsiriandsiiasbiomarkersandpredictorsoftreatmentefficacy AT marcinkurowski chronicurticariatreatmentwithomalizumabverificationofnlrplrsiriandsiiasbiomarkersandpredictorsoftreatmentefficacy AT annazalewskajanowska chronicurticariatreatmentwithomalizumabverificationofnlrplrsiriandsiiasbiomarkersandpredictorsoftreatmentefficacy |